anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A process of preparing a gallicin compound by extracting leaves of Acer ginnala Max. in an organic solvent is provided. Whereby, the extract of leaves of Acer ginnala Max. and a gallicin compound exhibit excellent anticancer activity and can be widely used as a natural anticancer agent. CONSTITUTION: An extract of leaves of Acer ginnala Max. contains gallicin(methyl-3,4,5-trihydroxybenzoate) of formula(I) and is effective for treatment of one cancer selected from the group consisting of human lung cancer, ovarian cancer, skin cancer, cancer of a central nervous system and colon cancer.
This is a randomized clinical intervention study with a cross-over design. The subjects are randomly allocated to one of the three experimental groups: 1) the control; 2) ASM group for aqueous single-phase mouthrinse; 3) OTM group for oil-water two-phase mouthrinse. The experimental mouthrinses all contain sodium fluoride and the ASM and OTM contain additional ingredients of bamboo salt, magnolia bark and centella asiatica extracts. For the OTM, 50% essential oil is added to create an oil-water two-phase mouthrinse. Subjects are instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen is followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen.
In SAD and MAD studies, all subjects are randomized in a 3:1 ratio. In SAD study , there are 6 cohorts (8 subjects/cohort) with dose levels of 10mg, 20 mg, 40 mg, 80 mg, 120 mg and 150 mg respectively. Blood samples will be collected for safety, PK and PD assessments. After the completion of Cohort 2 (20 mg) in SAD study, following a 7-day washout period, the same 8 subjects will receive another single oral dose of 20 mg HPG1860 after a standard high fat/high calorie breakfast (the fed condition). PK blood samplings will be collected and Cmax and AUC will be used for assessing the food effect. In MAD study, there are 3 cohorts (8 subjects/cohort) with dose levels of 10mg, 30mg and 90 mg, respectively and dosing regimen is once daily for 14 consecutive days. Blood samples will be collected for safety, PK and PD assessments.
Low dose chloroquine group consisted of 450 mg bid (3 tablets of 150 mg) on D1, and 3x150mg tablet once daily from D2 to D5. Oral administration or via a nasogastric tube in case of orotracheal intubation. (this was a second stage of the original study and was approved by the Brazilian IRB on 03/May/2020).
Hemiparetic gait disorders are common in stroke survivors. A circumductory gait is often considered the typical hemiparetic gait. In clinical practice, a wide spectrum of abnormal gait patterns is observed, depending on the severity of weakness and spasticity, and the anatomical distribution of spasticity. Muscle strength is the key determinant of gait disorders in hemiparetic stroke survivors. Spasticity and its associated involuntary activation of synergistic spastic muscles often alter posture of involved joint(s) and subsequently the alignment of hip, knee, and ankle joints, resulting in abnormal gait patterns. Due to combinations of various levels of muscle weakness and spasticity and their interactions with ground reaction force, presentations of gait disorders are variable. From a neuromechanical perspective, a stepwise visual gait analysis approach is proposed to identify primary underlying causes. In this approach, the pelvic and hip joint movement is examined first. The pelvic girdle constitutes three kinematic determinants. Its abnormality determines the body vector and compensatory kinetic chain reactions in the knee and ankle joints. The second step is to assess the ankle and foot complex abnormality. The last step is to examine abnormality of the knee joint. Assessment of muscle strength and spasticity of hip, knee, and ankle/foot joints needs to be performed before these steps. Lidocaine nerve blocks can be a useful diagnostic tool. Recognizing different patterns and identifying the primary causes are critical to developing clinical interventions to improve gait functions.
Evidence-based approaches for weight management in the United Kingdom are lacking. This study examined preferences for behavioural weight-management programmes amongst adults aged eighteen and over in Northern Ireland who had experience living with overweight (i.e., body mass index (BMI) ≥ 25 kg/m2). It involved the design and implementation of an online survey assessing previous experience with weight management and preferences for future weight-management programmes. A total of 94.7% of participants had previously engaged with weight-management services but many struggled to maintain weight loss. Older adults were more likely to be motivated to reduce their weight whilst younger adults were more likely be motivated to change their appearance. A focus on both wellbeing and weight-related outcomes was evident. Participants preferred programmes to be low-cost, delivered by a range of professionals by blended delivery, consisting of short (≤1 h) weekly sessions. These preferences highlighted important considerations for the components of future services to improve engagement and effectiveness.
Eligible patients were randomized in a 1:1 ratio to belimumab/placebo on the background of standard therapy. Placebo (normal saline) is administered intravenously at week 0, week 2, week 4 and then every 4 weeks until 48 weeks.
The study vaccine (fH1 2 ug and DSP-0546LP 2.5 ug) will be administered IM into the deltoid muscle of the non-dominant upper arm whenever possible. Subjects will receive 2 administrations at 3-week intervals.
RYZNEUTA is administered subcutaneously via a single-dose prefilled syringe by a healthcare professional.

Prior to use‚ remove the carton from the refrigerator (keeping the prefilled syringe inside the carton) for a minimum of 30 minutes to allow the product to reach room temperature. Discard any product left at room temperature for greater than 48 hours.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer RYZNEUTA if discoloration or particulates are observed.

Caution: This product contains natural rubber latex which may cause allergic reactions. The needle cap on the prefilled syringe contains natural rubber; people with latex allergies should not administer this product.

The RYZNEUTA prefilled syringe does not bear graduation marks and is intended only to deliver the entire contents of the syringe (20 mg/mL) for direct administration to adult patients.

Administer injection by pinching the skin and holding. Inject into the abdomen, the back or side of the upper arms, or the thighs. Rotate injection sites. Do not inject into scar tissue or areas that are reddened, inflamed, or swollen. If injecting into the abdomen, avoid a 2-inch diameter circle around the navel. Once the entire dose has been injected, the needle safety device will be triggered, pulling the needle automatically from the skin, and into the barrel; the entire needle will be covered by the needle guard.
PURPOSE:To provide the titled remedy containing carcitonir as an active component and effective for the prevention, remedy and treatment of arteriosclerosis. CONSTITUTION:The objective remedy for hypercholesterolemia is obtained by using a carcitonin (a peptide hormone composed of 32 amino acids, having a molecular weight of about 3,500 and having a cyclic structure formed with an S-S bond between the 1- and the 7-amino acids: e.g. salmon carcitonin, pig carcitonin, elcatonin, human carcitonin, etc.), as an active component. Dose: 10-200 IU, preferably 20-80 IU per day. It is administered generally by parenteral administration (e.g. intramuscular injection, intravenous injection, sublingual administration, rectal infusion, etc.). Since the agent is applied parenterally, there is no side effect such as disorder of the digestive organs. In the case of using the agent as an injection, it can be prepared in the form of liquid or freeze-dried product.
INTRODUCTION: Patients experience high symptom burden during critical care hospitalization and mechanical ventilation. Medications are of limited effectiveness and are associated with increased morbidity such as delirium and long-term cognitive and psychological impairments. Music-based interventions have been used for pain and anxiety management in critical care but remain understudied in terms of music selection and range of symptoms. This study aimed to describe the ways in which a diverse sample of critically ill adults used personalized music listening and their perceptions of the effects of music listening on symptom experience after critical injury.
METHODS: Semi-structured interviews (N = 14) of adult patients, families and friends who were provided with personalized music in an urban, academic, neurotrauma intensive care unit were collected and analyzed with grounded theory methodology. Open coding of transcripts, field notes and memos was performed using Atlas.ti.9.1. Recruitment and data collection were deemed complete once thematic saturation was achieved.
RESULTS: We identified 6 uses of personalized music listening in critical care: 1) Restoring consciousness; 2) Maintaining cognition; 3) Humanizing the hospital experience; 4) Providing a source of connection; 5) Improving psychological wellbeing; and 6) Resolving the problems of silence. Patients used music to address psychological experiences of loneliness, fear, confusion, and loss of control. Personalized music helped patients maintain their identity and process their trauma. Additional benefits of music included experiencing pleasure, hope, resilience, and feelings of normalcy. Patients disliked being sedated and used music to wake up. Findings also highlighted the problem of the lack of meaningful stimulation in critical care.
CONCLUSION: Critically injured adults used personalized music to achieve psychological and cognitive homeostasis during critical care hospitalization. These results can inform future studies designed to explore the use of music-based interventions to prevent and treat the cognitive and emotional morbidity of critical care.
Participants will receive RO5479599 in combination with cetuximab. Escalation of RO5479599 in combination with cetuximab will start in a standard 3+3 design until MTD/OBD is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of cetuximab and lower doses of RO5479599.
After completing baseline, participants will be invited to schedule a CARE session in 3 months (i.e., after the completion of all study assessments). The version of CARE received at that point will be selected by the survivor. Participants will complete self-report assessments at post-session-1, Month 1, Month 2, and Month 3.
Clinical Presentation   
Acute overdosage with hydrocodone can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension, hypoglycemia, partial or complete airway obstruction, atypical snoring, and death. Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations [see Clinical Pharmacology (12.2)]. 

Treatment of Overdose   
In case of overdose, priorities are the re-establishment of a patent airway and institution of assisted or controlled ventilation, if needed. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. Cardiac arrest or arrhythmias will require advanced life support measures. 

Opioid antagonists, such as naloxone, are specific antidotes to respiratory depression resulting from opioid overdosage. For clinically significant respiratory or circulatory depression secondary to hydrocodone overdose, administer an opioid antagonist.

Because the duration of opioid reversal is expected to be less than the duration of action of hydrocodone in hydrocodone bitartrate extended-release tablets, carefully monitor the patient until spontaneous respiration is reliably reestablished. Hydrocodone bitartrate extended-release tablets will continue to release hydrocodone and add to the hydrocodone load for 24 to 48 hours or longer following ingestion, necessitating prolonged monitoring. If the response to an opioid antagonist is suboptimal or only brief in nature, administer additional antagonist as directed by the product’s prescribing information. 

In an individual physically dependent on opioids, administration of the recommended dose of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal syndrome produced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be initiated with care and by titration with smaller than usual doses of the antagonist.
PROBLEM TO BE SOLVED: To obtain a medicine which inhibits selectively multiplication or metabolism of target cells, e.g. tumor cells and the like, without adverse effect on normal cells. SOLUTION: This is a medicine, e.g. an antitumor agent and the like, which contains an enzyme inhibitor as an active ingredient and satisfies below conditions. The enzyme inhibitor inhibits at least one enzyme (e.g. adenylosuccinic acid synthase) essential to the first pathway in the metabolism of essential compound (e.g. AMP, ADP, ATP, etc.) and does not inhibit the second pathway in the metabolism of the essential compound. The fijnction of enzyme (for example 5'-methylthioadenosine phospholylase and the like) essential to the second pathway is lost in target cells (e.g. human leukema cell strain CCRF-CEM, human neuroglioma cell strain A-172, etc,) of which multiplication is inhibited by the medicine. As the enzyme inhibitor, hydantocidine or hydantocidine derivative (for example hydantocidine-5'- monophosphate and the like) is illustrated.
FIELD: medicinal immunology. SUBSTANCE: mice are intravenously injected (into retroorbital venous plexus) with mink's serum at quantity of below 0.1 ml/mouse that leads to murine death. To study the action of inhibiting agent the latter is introduced simultaneously with mink's serum or 2 min before its injection. Its efficiency is determined by that its minimal introduced quantity which eliminates animal's death. The present innovation widens the number of techniques used in studying immune system in mammalians. EFFECT: higher efficiency. 1 ex, 1 tbl
This study is a Randomized Control Trial, which will be conducted in Shifa Tameer-e-Millat University (Department of Rehabilitation Sciences). the calculated Sample size is 24 individuals using Epitool with 95% Confidence Interval (CI) and power 80%. Individual will be screened out according to inclusion criteria. Individuals will be allocated randomly into two groups, 12 in High Intensity Aerobic training group and 12 in Low Intensity Aerobic Training group by sealed envelope method. High Intensity Aerobic Training will be use in experimental group. Low Intensity Aerobic Training will be used in Control group. Assessment will be done on baseline day 1 prior to the intervention and after 8 weeks of training.
Spatial heterogeneity of cells in liver biopsies can be used as biomarker for disease severity of patients. This heterogeneity can be quantified by non-parametric statistics of point pattern data, which make use of an aggregation of the point locations. The method and scale of aggregation are usually chosen ad hoc, despite values of the aforementioned statistics being heavily dependent on them. Moreover, in the context of measuring heterogeneity, increasing spatial resolution will not endlessly provide more accuracy. The question then becomes how changes in resolution influence heterogeneity indicators, and subsequently how they influence their predictive abilities. In this paper, cell level data of liver biopsy tissue taken from chronic Hepatitis B patients is used to analyze this issue. Firstly, Morisita-Horn indices, Shannon indices and Getis-Ord statistics were evaluated as heterogeneity indicators of different types of cells, using multiple resolutions. Secondly, the effect of resolution on the predictive performance of the indices in an ordinal regression model was investigated, as well as their importance in the model. A simulation study was subsequently performed to validate the aforementioned methods. In general, for specific heterogeneity indicators, a downward trend in predictive performance could be observed. While for local measures of heterogeneity a smaller grid-size is outperforming, global measures have a better performance with medium-sized grids. In addition, the use of both local and global measures of heterogeneity is recommended to improve the predictive performance.
The present invention relates to a material for regulating the polarization and immune function of a macrophage and the use thereof. Particularly, disclosed is a particle crystal coating having the effect of inhibiting pro-inflammation. The particle crystal coating is formed by means of self-assembly of microspheres and micro-nanospheres on the surface of a substrate. The micro-nanospheres include polymethyl methacrylate (PMMA) micro-nanospheres with at least one particle size. The microspheres are selected from oxidized inorganic microspheres or polymer organic microspheres. The particle size of the microspheres is 1 μm to 6 μm and the particle size of the micro-nanospheres is selected from 50 nm to 500 nm. Provided is a particle crystal coating surface for inhibiting the polarization of a macrophage. A large number of surface topography combinations are obtained by means of adjusting the types and proportions of particles using particle self-assembly technology. Such surface combinations can be used for high-throughput screening of surface topography.
OBJECTIVE: Our objective was to evaluate the feasibility of XperCT combined fluoroscopy to guide sharp recanalization for the treatment of chronic thoracic venous occlusive disease in hemodialysis patients.
METHODS: The records of hemodialysis patients with chronic thoracic venous occlusive disease who received endovascular sharp recanalization after conventional techniques failed were retrospectively reviewed. The sharp devices used for recanalization included the stiff end of a guidewire, Chiba biopsy needle, RUPS-100 set, and transseptal needle. The needle was advanced toward a target placed at the opposite end of the occlusion and was guided by fluoroscopy and/or XperCT. While the guidewire crossed the occlusion, endovascular procedures such as percutaneous angioplasty were performed for the treatment of the occlusion.
RESULTS: The analysis included 32 sharp thoracic vein recanalization procedures in 29 patients. Two attempts in one patient failed, and in one patient the first attempt failed but the second attempt was successful. In one patient, two separate successful procedures were performed, and the other 26 procedures in 26 patients were successful. The overall technical success rate of sharp recanalization was 90%. The mean number of puncture attempts in the combined group was less than that of the fluoroscopy-guided alone group (2 vs 5, p < 0.05). The success rate of sharp recanalization in the combined group was higher (100% vs 86%), and the recanalization time (28.5 min vs 36 min, p > 0.05) was no different. There was no statistical difference in procedure-related complications between the groups.
CONCLUSION: XperCT can facilitate sharp recanalization for the treatment of chronic thoracic venous occlusive disease in hemodialysis patients.
PROBLEM TO BE SOLVED: To obtain a safe and persistent external agent exhibiting excellent antiphotooxidation action by combining a specific antioxidation agent including chlorogenic acid with an electron donor. SOLUTION: This agent is produced by using an antioxidation agent having photoregenerating action and free from activity to reduce oxygen in the photoregeneration reaction in combination with an electron donor necessary for the regeneration of the antioxidation agent. The antioxidation agent is preferably one or more components selected from o-hydroxyphenol compound, especially chlorogenic acid and coffeic acid. The electron donor is preferably sugars or EDTA. The amount of the antioxidation agent is preferably 0.001wt.%, especially 0.001-1.0wt.% based on the total external agent. The compounding molar ratio of the electron donor to the antioxidation agent is preferably >=5. The antiphotooxidation agent for external use is useful as cosmetics, drugs, quasi-drugs, etc., especially an antiultraviolet agent for external use, especially external agent for skin or hair.
Social pain sharing promotes cooperation, but we still don't know its neural basis. The present study employed functional near-infrared spectroscopy (fNIRS)-based hyperscanning technology to investigate whether interpersonal brain synchronization (IBS) increased between females engaging in cooperative activities after a shared experience of social pain. We utilized the Cyberball paradigm, manipulating social pain by regulating the number of catches for the participants. Dyads in the shared social pain (SP) group received passes only at the beginning of the game, whereas dyads in the control (CT) group had the same number of catches as other players. The results indicate that participants in the SP group showed significant IBS in the right superior frontal cortex (r-SFC, p < 0.05) and left middle frontal cortex (l-MFC, p < 0.05), but no channels in the CT group showed significant IBS (p > 0.05). Further analysis revealed that IBS in r-SFC was significantly higher in the SP group compared to the CT group (p < 0.05). Additionally, IBS in r-SFC was positively correlated with the level of cooperation (r = 0.66, p < 0.001). This study elucidates the neural basis of enhanced cooperation facilitated by shared social pain at the interbrain level. However, it is crucial to acknowledge that this study exclusively enrolled female participants. The generalizability of these findings across genders is yet to be confirmed.
The goal of the proposed, proof-of-concept study is to test the combined effects of vaporized marijuana \[Delta-9-tetrahydracannabinol (THC)\] with NLX as a proof of concept towards the possible development of a combined overdose reversal agent with improved tolerability. Marijuana plant material will be obtained from the National Institutes on Drug Abuse (NIDA). In clinical studies, oral synthetic THC reduced the severity of opioid withdrawal during opioid detoxification. Clinically, cannabinoid drugs like Marinol® (oral synthetic THC), Sativex ® (nabixomols), and Cesamet® (nabilone) are used to treat nausea and vomiting, common symptoms of opioid withdrawal. This study will investigate the ability of vaporized marijuana (V-MJ) (0.00, 12.5, and 25 mg: concentration= 11.7% THC + 0.04% CBD) to reduce the severity of opioid withdrawal precipitated by intranasal (IN) NLX (0.0 and 4.0 mg). This trial will recruit healthy participants with opioid use disorder (N=16, completers). Testing will begin following stabilization on oral morphine (120 mg/day), which will continue throughout the trial. During each testing session, a single V-MJ + naloxone dose combination will be assessed (in randomized order), with 48 hours between testing sessions. Laboratory testing sessions will consist of a modified naloxone challenge procedure, which quantifies the severity of naloxone-precipitated opioid withdrawal.